Teva announces new analysis of consistency in migraine days over the course of a dosing regimen for ajovy® (fremanezumab-vfrm) injection published in headache

Teva pharmaceutical industries ltd. (nyse and tase: teva) today announced results from a post hoc analysis of a long-term, open-label extension study

DECK Ratings Summary

DECK Quant Ranking